The USA-based not-for-profit Institute for Clinical and Economic Review (ICER) will develop a report assessing the comparative clinical effectiveness and value of chimeric antigen receptor T-cell (CAR-T) therapies for treatment of certain types of cancer.
The report is tentatively expected to consider two therapies currently under review by the US Food and Drug Administration: axicabtagene ciloleucel, from US biotech firm Kite Pharmaceuticals (Nasdaq: KITE), and tisagenlecleucel-t, from Swiss pharma giant Novartis (NOVN: VX).
If approved, axicabtagene ciloleucel is expected to be used in the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma in adult patients who are not eligible for autologous stem cell transplant. An approval decision is expected in December of 2017, following a Biologics License Application filing in April.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze